ArticleThe Journal of infectious diseases2025
Serum IgG1 and IgG3 Antibody Responses to Chlamydia trachomatis Pgp3 and Hsp60 in Tubal Factor Infertility.
Article in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Serum IgG1 and IgG3 Antibodies to Chlamydia trachomatis Pgp3 and Hsp60 in Men of Subfertile Couples.The Journal of infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundOur goal was to investigate IgG1 and IgG3 antibody responses to Chlamydia trachomatis proteins Pgp3 and Hsp60 in women with tubal factor infertility (TFI). Our goal was to determine the role of these biomarkers in the diagnosis of C. trachomatis-associated TFI, and assess their sensitivity and specificity for detecting tubal pathology.
methodsSerum samples were collected from 258 subfertile women, and 34 women positive for C. trachomatis by nucleic acid amplification test (NAAT). IgG1 and IgG3 antibodies to Pgp3 and Hsp60 were measured using enzyme immune assays.
resultsPgp3 IgG1 antibodies were detected in 68.2% of TFI cases and 31.8% of controls (non-TFI), while Hsp60 IgG1 antibodies were found in 36.4% of TFI cases. Pgp3 IgG1 had the highest sensitivity for TFI (68.2%; 95% confidence interval [CI], 45.1%-86.1%), while Hsp60 IgG3 was the most specific (93.6%; 95% CI, 89.7-96.4). Antibody levels increased with tubal damage severity. Among the 34 NAAT-positive women, 78.8% were positive for Pgp3 IgG1.
conclusionsPgp3 IgG1 antibody was a sensitive marker for detecting C. trachomatis-related TFI, while Hsp60 IgG3 antibody was highly specific. These findings suggest that Pgp3 and Hsp60 antibodies and antibody subclass testing may be useful diagnostic tools for assessing TFI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.